Insights into the molecular alterations of PLAG1 and HMGA2 associated with malignant phenotype acquisition in pleomorphic adenoma

IF 5.5 2区 医学 Q1 HEMATOLOGY
Reydson Alcides de Lima-Souza , Gustavo de Souza Vieira , Talita de Carvalho Kimura , João Figueira Scarini , Luccas Lavareze , Tayná Figueiredo Maciel , Moisés Willian Aparecido Gonçalves , Erika Said Abu Egal , Albina Altemani , Fernanda Viviane Mariano
{"title":"Insights into the molecular alterations of PLAG1 and HMGA2 associated with malignant phenotype acquisition in pleomorphic adenoma","authors":"Reydson Alcides de Lima-Souza ,&nbsp;Gustavo de Souza Vieira ,&nbsp;Talita de Carvalho Kimura ,&nbsp;João Figueira Scarini ,&nbsp;Luccas Lavareze ,&nbsp;Tayná Figueiredo Maciel ,&nbsp;Moisés Willian Aparecido Gonçalves ,&nbsp;Erika Said Abu Egal ,&nbsp;Albina Altemani ,&nbsp;Fernanda Viviane Mariano","doi":"10.1016/j.critrevonc.2024.104494","DOIUrl":null,"url":null,"abstract":"<div><div>Pleomorphic adenoma (PA) is the most common neoplasm of the salivary gland, presenting with a variety of histological features. In some cases, PA can undergo malignant transformation to carcinoma ex pleomorphic adenoma (CXPA). The transition from PA to CXPA is associated with complex molecular alterations, particularly involving the <em>pleomorphic adenoma gene 1</em> (<em>PLAG1</em>) and <em>high mobility group protein gene</em> (<em>HMGA2</em>). This review investigates the molecular alterations of PLAG1 and HMGA2 in all domains in the malignant transformation of PA. Our analysis highlights that these markers are key alterations in the etiopathogenesis of PA and CXPA, with gene fusion and amplification being frequently reported mechanisms. Although the exact role of PLAG1 and HMGA2 in the oncogenic process remains unclear, further studies on the HMGA2 and PLAG1, are needed particularly in HMGA2-PLAG1-IGF2 which is proving to be a potential pathway for the development of clinically applicable therapies, especially for CXPA management.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104494"},"PeriodicalIF":5.5000,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in oncology/hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1040842824002373","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Pleomorphic adenoma (PA) is the most common neoplasm of the salivary gland, presenting with a variety of histological features. In some cases, PA can undergo malignant transformation to carcinoma ex pleomorphic adenoma (CXPA). The transition from PA to CXPA is associated with complex molecular alterations, particularly involving the pleomorphic adenoma gene 1 (PLAG1) and high mobility group protein gene (HMGA2). This review investigates the molecular alterations of PLAG1 and HMGA2 in all domains in the malignant transformation of PA. Our analysis highlights that these markers are key alterations in the etiopathogenesis of PA and CXPA, with gene fusion and amplification being frequently reported mechanisms. Although the exact role of PLAG1 and HMGA2 in the oncogenic process remains unclear, further studies on the HMGA2 and PLAG1, are needed particularly in HMGA2-PLAG1-IGF2 which is proving to be a potential pathway for the development of clinically applicable therapies, especially for CXPA management.
洞察多形性腺瘤恶性表型获得过程中 PLAG1 和 HMGA2 的分子变化。
多形性腺瘤(PA)是唾液腺最常见的肿瘤,具有多种组织学特征。在某些情况下,多形性腺瘤会恶变为癌外多形性腺瘤(CXPA)。从 PA 到 CXPA 的转变与复杂的分子改变有关,尤其涉及多形性腺瘤基因 1(PLAG1)和高迁移率基团蛋白基因(HMGA2)。本综述研究了 PA 恶性转化过程中 PLAG1 和 HMGA2 在各个领域的分子改变。我们的分析强调,这些标志物是 PA 和 CXPA 病因发病机制中的关键改变,基因融合和扩增是经常报道的机制。尽管 PLAG1 和 HMGA2 在致癌过程中的确切作用仍不清楚,但仍需对 HMGA2 和 PLAG1 进行进一步研究,特别是 HMGA2-PLAG1-IGF2 的研究,因为事实证明,HMGA2-PLAG1-IGF2 是开发临床适用疗法(特别是 CXPA 治疗)的潜在途径。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
11.00
自引率
3.20%
发文量
213
审稿时长
55 days
期刊介绍: Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信